A new trading day began on Tuesday, with Aquestive Therapeutics Inc (NASDAQ: AQST) stock price down -4.95% from the previous day of trading, before settling in for the closing price of $2.83. AQST’s price has ranged from $2.20 to $5.80 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 2.34% over the past five years. Meanwhile, its annual earnings per share averaged -30.07%. With a float of $88.18 million, this company’s outstanding shares have now reached $91.41 million.
Let’s look at the performance matrix of the company that is accounted for 142 employees. In terms of profitability, gross margin is 68.95%, operating margin of -53.46%, and the pretax margin is -76.7%.
Aquestive Therapeutics Inc (AQST) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Aquestive Therapeutics Inc is 11.22%, while institutional ownership is 38.73%. The most recent insider transaction that took place on Nov 26 ’24, was worth 214. In this transaction Chief Operating Officer of this company sold 44 shares at a rate of $4.87, taking the stock ownership to the 0 shares.
Aquestive Therapeutics Inc (AQST) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -30.07% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 13.68% during the next five years compared to 27.90% growth over the previous five years of trading.
Aquestive Therapeutics Inc (NASDAQ: AQST) Trading Performance Indicators
Here are Aquestive Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.36. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.64.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.52, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach -0.56 in one year’s time.
Technical Analysis of Aquestive Therapeutics Inc (AQST)
Aquestive Therapeutics Inc (NASDAQ: AQST) saw its 5-day average volume 0.96 million, a negative change from its year-to-date volume of 1.51 million. As of the previous 9 days, the stock’s Stochastic %D was 43.76%. Additionally, its Average True Range was 0.19.
During the past 100 days, Aquestive Therapeutics Inc’s (AQST) raw stochastic average was set at 27.45%, which indicates a significant decrease from 38.53% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 50.24% in the past 14 days, which was lower than the 67.72% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.80, while its 200-day Moving Average is $3.80. Nevertheless, the first resistance level for the watch stands at $2.78 in the near term. At $2.88, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.94. If the price goes on to break the first support level at $2.62, it is likely to go to the next support level at $2.56. The third support level lies at $2.46 if the price breaches the second support level.
Aquestive Therapeutics Inc (NASDAQ: AQST) Key Stats
With a market capitalization of 267.17 million, the company has a total of 99,321K Shares Outstanding. Currently, annual sales are 57,560 K while annual income is -44,140 K. The company’s previous quarter sales were 11,870 K while its latest quarter income was -17,060 K.
